BioSpace News Archive

FX Shoulder USA, Inc. will begin in December 2018 the FDA approved Investigational Device Exemption (IDE) clinical study of the Easytech Reversed stemless, a shoulder prosthesis, with its first implantation scheduled for December

Community Hospital Corporation (CHC), a national leader in community hospital operations, announced the company is concluding a strong year amid challenging times for community hospital

Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase I clinical study of Tegavivint, its lead therapeutic candidate, in patients with desmoid tumors that are unresectable and symptomatic or progressive.

- FSD Pharma to work with Canntab to create tablets for the clinical research study at its facility in Cobourg, Ontario, Canada -

“I’m a nurse and I thought there could be a better way to use hand sanitizer while working,” said an inventor, from Tampa, Fla., “so I invented the PERSONAL PROTECTIVE SANITIZER.”

“Our son suffered with Molluscum and the current products to treat this skin infection were ineffective and caused a stinging pain,” said an inventor from Alma, Ga. “This inspired me to develop a topical cream which may help to eliminate this infection.”

CHOP Celebrates Landmark Medical Advance: The First Gene Therapy for a Genetic Disease Approved in Both the U.S. and Europe

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the construction of new biologics drug substance manufacturing facility has commenced on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth.

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, is pleased to note the announcement today by Norgine that they have launchedFeraccru® in the UK.

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that Scientific Advisory Board Member, Donald B. Kohn, MD, presented clinical proof-of-concept data from an ongoing academic clinical trial evaluating OTL-102 for the treatment of X-Linked Chronic Granulomatous Disease